Compare GGAL & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGAL | RGEN |
|---|---|---|
| Founded | 1905 | 1981 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.6B |
| IPO Year | 2001 | 1995 |
| Metric | GGAL | RGEN |
|---|---|---|
| Price | $44.97 | $172.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $69.00 | ★ $167.67 |
| AVG Volume (30 Days) | 894.1K | ★ 976.8K |
| Earning Date | 03-07-2023 | 05-05-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $141,236,000.00 |
| Revenue This Year | $62.29 | $14.30 |
| Revenue Next Year | $22.88 | $14.52 |
| P/E Ratio | ★ $13.36 | $708.42 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $25.89 | $100.99 |
| 52 Week High | $62.11 | $188.73 |
| Indicator | GGAL | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 56.11 |
| Support Level | $44.86 | $156.65 |
| Resistance Level | $45.07 | $173.10 |
| Average True Range (ATR) | 1.77 | 7.17 |
| MACD | 0.40 | -1.35 |
| Stochastic Oscillator | 94.58 | 34.67 |
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.